Epigenomics Studies in Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML) remains a clinical challenge since most patients diagnosed with AML will die from the disease. Some patients harbor treatment-refractory disease and many others relapse with disease that in many cases is resistant to treatments. Our study was designed to understand the molecular basis of disease progression in AML through assessing genomics signatures in patient specimens collected through an international collaboration which assembled samples from 138 AML patients which experienced disease relapse and normal hematopoietic cells (n=15). It is hoped that this resource will help researchers understand mechanisms of disease relapse in AML and contribute to the general pool of data available for analyses for this disease and general research use.]]>
Inclusion and exclusion criteria for specimens included: Inclusion criteria: patients diagnosed with non-M3 Acute Myeloid Leukemia (AML), who received induction chemotherapy treatment with combination chemotherapy including, but not limited to an anthracycline and cytosine arabinoside, and patients from whom specimens with high blast cell percentages were available from diagnosis and relapse time points. Patient-matched germline specimens were collected in a sub-set of patients, and age-matched controls were obtained from individuals without any known hematological conditions with CD34+ cell enrichment greater than 90%. Exclusion criteria: patients with M3 AML (Acute Promyelocytic Leukemia), patients who received treatments not including an anthracycline and cytosine arabinoside during induction treatment, patients who relapsed more than five years after the original diagnosis.]]>
N/A - specimens were not part of a specific clinical trial]]>